This disclosure relates to mRNA therapy for (i) the promotion and/or improvement of wound healing, (ii) the prevention and/or reduction of scar formation at a wound, (iii) the reduction of the visibility of a scar, and/or (iv) the treatment of epidermolysis bullosa. mRNAs for use in the invention, when intradermally (e.g., using microneedles) or topically administered in vivo, encode a wound healing polypeptide (e.g., a growth factor, a cytokine, a chemokine, a protease inhibitor, or a collagen).

Mucoadhesive microgel compositions, which include an active agent (such as HB-EGF), are provided. Aspects of the invention include a microgel comprising a crosslinked poly(ethylene glycol) methyl ether methacrylate polymer comprising a mucoadhesive functionality. Also provided are methods of making and using the mucoadhesive microgel compositions, e.g., in therapeutic applications. In one embodiment, HB-EGF loaded mucoadhesive microgel compositions are provided, e.g., for prevention or treatment of mucositis conditions, such as therapy induced oral mucositis conditions.

A hydrogel prepared through the supramolecular self-assembly of cyclodextrin and adamantane is described. The hydrogel can be filled with drugs and cells and used for various diseases. The hydrogel uses hyaluronic acid and thus can be applied to transdermal delivery, in vivo drug release, intractable disease treatment using stem cells, etc.

Cell-free compositions for promoting restoration of tissue function or enhancement of tissue function and methods of stimulating or promoting restoration or enhancement of tissue function using the cell-free compositions. The compositions herein help stimulate endogenous pathways via a subject's own cells effectively for improving tissue function, enhancing tissue function, enhancing cell proliferation, etc. The compositions comprise one or a plurality of therapeutic components such as growth factors, extracellular matrix, DNA, RNA, hormones, drugs, cell surface receptors, enzymes, cytokines, angiogenesis modulating factors, etc., e.g., any material that can effectively activation endogenous pathways in the subject's own cell to a desired effect. The cell-free composition comprises a carrier or is attached to or integrated into and/or within a carrier. The carrier may help provide for containment of the therapeutic components and/or provide for time-release of the therapeutic components of the cell-free composition.

Cells derived from postpartum tissue and methods for their isolation and induction to differentiate to cells of a chondrogenic or osteogenic phenotype are provided by the invention. The invention further provides cultures and compositions of the postpartum-derived cells and products related thereto. The postpartum-derived cells of the invention and products related thereto have a plethora of uses, including but not limited to research, diagnostic, and therapeutic applications, for example, in the treatment of bone and cartilage conditions.

A composition for influencing biological growth including live cells, a fluid comprising dextrose, a protectant, and a first cytokine having a first concentration within the composition as described within the present disclosure.

Methods of treating auditory disorders with modulators of the WNT signaling pathway are disclosed. Also provided are methods of administration and pharmaceutical compositions.

Methods of treating auditory disorders with modulators of the WNT signaling pathway are disclosed. Also provided are methods of administration and pharmaceutical compositions.

The present invention reveals the use of epidermal growth factor (EGF) for the manufacture of an injectable medicament for the treatment of a diabetic foot ulcer (DFU), in a patient without criteria of amputation of the affected limb at the time of the clinical evaluation, wherein the medicament comprising EGF is administered by intralesional infiltration in said ulcer once a week. Moreover, it provides a pharmaceutical composition comprising EGF, for the treatment of a DFU in a patient, where the composition is administered once a week. The invention comprises a method for the treatment of a DFU in a patient, without criteria of amputation of the affected limb at the time of the clinical evaluation, comprising administering EGF to the patient, by intralesional infiltration in the ulcer base once a week.

Various embodiments are described herein for the fabrication enzyme degradable hydrogels useful as payload delivery systems. More particularly, embodiments disclosed herein relate to enzyme-degradable hydrogel systems comprising a crosslinkable polymer, such as a chemically-modified biopolymer, for example, chemically-modified gelatin, the hydrogel formed by a method comprising sequential physical and chemical crosslinking steps, for delivery of various payloads. Enzymes may be selected and administered to tune the release profile of the hydrogel. The payload can be, but not limited to, drugs, markers, cells, or these members encapsulated within another drug delivery such as a nanoparticle, or liposome. The hydrogel system can also be combined with another device such as a contact lens or bandage for wound healing.